+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Market Access Impact: Psoriasis (US) 2018

  • ID: 4521405
  • Report
  • February 2018
  • Region: Global
  • FirstWord Publishing

Market barriers affect nearly 30% of psoriasis prescriptions. Is your brand losing out?

In the US, where market barriers affect nearly 30% of all psoriasis prescriptions, the top brand has a significant lead over all other brands. Find out what’s driving its share gains, and what your brand can do to level the playing field in Market Access Impact: Psoriasis (US) [2018].

Based on a survey of 100 dermatologists, the report covers 8 major therapies from Amgen, Novartis, AbbVie, Celgene, Valeant, Janssen Biotech and Eli Lilly. Handy graphs and charts reveal which of the 7 different barriers cost your brand the most market share, and which ones help you take the most from competitors.

Top Takeaways
  • Barriers affect nearly 30% of all prescriptions: But is it cost, formulary issues or some other barrier combinations that cause the most amount of pain?
  • Only one brand sees a significant share increase: 3 brands gain share thanks to barriers, but the top-gaining brand sees a much bigger bump than the other two.
  • Two brands see significant losses: One of the least prescribed brands loses nearly 4% of their market share because of barriers. Why? And can this be prevented?
  • Eliminating barriers would close the gap at the top: The leading brand relies on other brands losing out. Removing these barriers would have a massive impact on market share for two brands. Are they yours, or one of your competitors?
  • One brand has a perception problem: Nearly a fifth of surveyed doctors would not prescribe a specific brand, leaving other brands to capture market share.

Insight into Major Psoriasis Drugs
  • Cosentyx (secukinumab; Novartis)
  • Enbrel (etanercept; Amgen)
  • Humira (adalimumab; AbbVie)
  • Otezla (apremilast; Celgene)
  • Siliq (brodalumab; Valeant)
  • Stelara (ustekinumab; Janssen Biotech)
  • Taltz (ixekizumab; Eli Lilly)
  • Tremfya (guselkumab; Janssen Biotech)

Exploring Market Access Barriers

Market Access Impact: Psoriasis (US) explores key issues affecting Psoriasis drug manufacturers. You’ll learn:

How barriers affect market access:
  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest impact?

How barriers affect your brand:
  • How many doctors prescribe your brand? How many don’t, but would consider it?
  • Why don’t doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 100 US-based dermatologists, chosen from the largest community of validated physicians in the world.

All respondents:
  • Have been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients in total in the last month

We conducted the survey between February 6-15, 2018.
Note: Product cover images may vary from those shown

1.What are market barriers?

2.About this report

3.About the survey

4.Brands included in the survey

5.Executive summary

Note: Product cover images may vary from those shown